Objectives-To determine whether imaging and clinicopathologic features could predict false-positive axillary ultrasound (US) results in the selection of patients with breast cancer who had a heavy axillary tumor burden (3 tumor-involved nodes).
S
taging of the axilla is important in guiding adjuvant treatment for breast cancer. For approximately a century, axillary lymph node staging was routinely performed by axillary lymph node dissection (ALND) in all patients with breast cancer. Because of the high morbidity of ALND and high rate of negative dissection results, sentinel lymph node biopsy (SLNB) has been widely adopted as a less-invasive surgical approach for axillary staging. Patients with breast cancer who have clinically negative axillae are staged by SLNB, and those with positive SLNB results undergo further dissection. However, with the effective systemic adjuvant treatment currently available, management of the axilla in patients with earlystage breast cancer has been revolutionized. The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial showed no additional benefit to ALND for patients with clinical T1 or T2 node-negative tumors undergoing breast-conserving therapy with metastasis in 1 or 2 sentinel lymph nodes.
1,2 These findings suggest that only patients with breast cancer who have 3 or more axillary metastases should undergo ALND. 3, 4 Axillary ultrasound (US) is the most studied and effective imaging modality for assessing the lymph node status in women with newly diagnosed breast cancer. Since the results of the ACOSOG Z0011 trial have been widely adopted, the role of axillary US in the preoperative axillary staging of early-stage invasive breast cancer should be redefined. Intuitively, after the ACOSOG Z0011 trial, it has become insufficient for axillary US to only determine whether axillary involvement is present, and it is necessary to quantify the axillary load to assist surgical planning. It has been well documented that patients with negative axillary US findings generally have lower axillary metastatic loads, and those with suspicious axillary US findings have a greater nodal disease burden more frequently. [5] [6] [7] [8] Previous studies found that normal axillary US results could exclude pN2 and pN3 axillary disease for more than 95% of patients with invasive breast cancer. [5] [6] [7] In 2015, Jackson et al 8 reported that patients with suspicious lymph nodes on axillary US examinations were more likely to have 3 or more positive nodes in the final pathologic examination than those with negative axillary US findings (31.9% and 3.8%, respectively; P < .001). In their study, axillary US had sensitivity of 71% and specificity of 83% for detecting 3 or more nodal metastases in patients with newly diagnosed invasive breast carcinoma. Together, these data suggest that preoperative axillary US could still be used as an effective tool for selecting patients at risk of having 3 or more metastatic axillary nodes in the post-Z0011 trial era.
The preoperative identification of metastatic disease in patients with abnormal lymph nodes detected by axillary US has become a routine practice in many breast units, eliminating the need for SLNB and allowing patients to directly proceed to ALND. However, since the results of the ACOSOG Z0011 trial were implemented clinically, the decision to preoperatively biopsy the axilla has become less straightforward. Hieken et al 9 first reported that the false-positive rate of suspicious axillary US results for identifying 3 or more positive lymph nodes in the final pathologic examination was 79.8%. Of the 263 axillae with suspicious lymph nodes detected by axillary US included in their study, only 20.2% of cases (53 of 263) had 3 or more metastatic nodes, and the remaining 210 cases had less than 3 metastatic nodes in the final pathologic examination, including 89 with 1 or 2 metastatic nodes and 121 with no axillary metastasis. In this situation, performing preoperative biopsy on every case with abnormal lymph nodes would not only result in a distinct increase in health care costs; more importantly, it also might identify minimal nodal disease (1 or 2 positive nodes) in patients who otherwise would have qualified for SLNB alone under the ACOSOG Z0011 criteria, leading to unnecessary ALND. Thus, limiting the applicability of US-guided sampling to appropriately selected patients should be adopted in the post-Z0011 trial era. However, the exact subgroup of patients who do not require US-guided fine-needle aspiration for a positive axillary US result remains unclear.
The goal of this retrospective study was to investigate the false-positive rate of suspicious axillary US results for identifying axillae with a heavy nodal tumor burden, which was defined as 3 or more axillary lymph nodes containing metastases. Additionally, related imaging and clinicopathologic factors that might account for the false-positive results were also determined.
Materials and Methods

Patients
This retrospective study was approved by the Institutional Review Board, and a waiver of informed consent was granted on the basis of the retrospective nature of the study and minimal risk to patients. Between October 1, 2014, and September 31, 2015, 788 patients with newly diagnosed breast cancer underwent breast US examinations before surgery at Ruijin Hospital. At our institution, a US evaluation of the ipsilateral axilla was routinely performed during breast US examinations. Among these cases, 291 axillae had suspicious axillary lymph nodes present on US imaging. Among them, 124 axillae were excluded: (1) 15 cases had a pathologic tumor size of greater than 5 cm; (2) 80 cases had neoadjuvant chemotherapy; (3) 7 cases had distant metastasis at diagnosis; (4) 2 cases had breast surgery alone; (5) 8 cases had internal mammary nodal involvement, ipsilateral supraclavicular lymph nodal involvement, or both; and (6) 12 cases had a tissue diagnosis of atypical ductal hyperplasia or ductal carcinoma in situ without invasion on core biopsy. Therefore, 162 patients with 167 axillae (5 patients had bilateral breast cancers and underwent bilateral axillary US scans) were included in this study.
Axillary US Examinations
Preoperative axillary US examinations were performed by 2 licensed radiologists who had at least 5 years of experience in breast imaging. Ultrasound equipment included MyLab 60 and MyLab 90 machines equipped with high-resolution 10-MHz linear array transducers (Esaote SpA, Genoa, Italy). During the US examination, each patient was placed in a supine or oblique position to flatten the axillary fossa on the table with the ipsilateral hand placed behind the head. The entire axilla was scanned carefully to detect as many lymph nodes as possible. The focus, gain, and depth were adjusted to obtain the best possible image. All images were recorded and uploaded to a picture archiving and communication system for a later retrospective analysis.
At our institution, the axillary nodes were assessed for the following characteristics: (1) the morphologic features of the cortex; and (2) the presence or absence of the fatty hilum. The maximum cortical thickness was measured perpendicular to the long axis of the lymph node on a cross-sectional plane. The cortical thickness of nodes without a fatty hilum was measured as half the short axis of the node. The following criteria were used to identify suspicious lymph nodes: cortical thickening of greater than 3 mm and effacement of the fatty hilum. 10 Lymph nodes that did not meet these criteria were characterized as nonsuspicious for metastases. The original axillary US result was considered suspicious when at least 1 node that was suspicious for metastasis was present on the US scan.
Surgical and Pathologic Techniques for Axillary Lymph Nodes
Sentinel lymph node biopsy or ALND was routinely performed by experienced breast surgeons who had treated more than 100 patients with breast cancer per year. Patients with metastatic lymph nodes shown by fine-needle aspiration cytology (FNAC) were treated with direct ALND, whereas those without positive FNAC results received SLNB. During surgery, frozen pathologic testing was used to evaluate the sentinel lymph node status. If sentinel lymph node metastases were detected by a frozen-section analysis, ALND was performed. If metastases, except for micrometastases, were not detected during surgery, completion ALND was generally performed later.
The pathologist described the nodal stage according to the seventh edition of the American Joint Committee on Cancer (Chicago, IL) Breast Cancer Staging Manual. Nodal metastasis was defined as the presence of macrometastasis (>2.0 mm) or micrometastasis (>0.2 but 2.0 mm). Lymph nodes with only isolated tumor cells (< 0.2 mm) were considered negative.
Data Analyses
Medical records and US images were retrospectively collected in the analyses. Clinical findings included patient age, size of the primary breast tumor, primary tumor characteristics (tumor histologic type, histologic tumor grade, lymphatic vessel invasion, estrogen receptor [ER] status, progesterone receptor [PR] status, and c-erbB-2 expression) and total number of lymph nodes with metastasis from either ALND or SLNB. Tumor size was determined as the largest dimension of the tumor by histopathologic estimation and was categorized as T1 (tumor size 2 cm) and T2 (tumor size >2 but 5 cm). Axillary US findings included the total number of suspicious lymph nodes identified by axillary US and the US appearance of the most suspicious node.
Sentinel lymph node biopsy and ALND were considered reference standards. As proposed by the Z0011 trial, the nodal disease burden was categorized as a limited nodal tumor burden (without or with 1 or 2 tumorinvolved lymph nodes) and a heavy nodal tumor burden (3 tumor-involved lymph nodes). Next, we classified the patients with suspicious axillary US findings as follows: (1) false-positive group, having limited tumorinvolved axillary nodes at the final pathologic examination; and (2) true-positive group, having 3 or more tumor-involved axillary nodes at the final pathologic diagnosis. Statistical analyses were performed with the SPSS version 13.0 statistical software package (IBM Corporation, Armonk, NY). Between-group differences were compared by an independent t test for continuous variables and a v 2 or Fisher exact test for discontinuous variables. A binary logistic regression analysis was used to detect features that might have predicted falsepositive axillary US results independently, which were presented as risk ratios. For all tests, P < .05 was considered statistically significant.
Results
The mean age of patients 6 SD was 53.8 6 10.4 years (range, 28-80 years), and all patients were female. The final histologic results showed that 151 cases (90.4%) were invasive ductal carcinomas; 5 (3.0%) were invasive lobular carcinomas; and the remaining 11 (6.6%) involved rarer subtypes, including mucinous carcinoma (5 cases) and invasive micropapillary carcinoma (6 cases). Other demographics and tumor characteristics of the study population are listed in Table 1 .
Of the 167 axillae with suspicious lymph nodes on axillary US enrolled in the study, 54 (32.3%) showed no axillary metastasis, and 113 (67.7%) were positive for metastatic carcinoma on SLNB or ALND, including 47 with 1 or 2 metastatic nodes and 66 with 3 or more metastatic nodes. Concerning the extent of axillary nodal involvement, 101 cases (60.5%) had a limited nodal tumor burden, and the remaining 68 cases (39.5%) had a heavy nodal tumor burden. Thus, axillary US had a false-positive rate of 60.5% (101 of 167) in the patients with a heavy nodal burden.
Univariate Analyses Between the False-Positive Axillary US Results in Predicting Patients With a Heavy Nodal Burden and Multiple Factors
There was a significant association between tumor size and false-positive axillary US results in the selection of patients with heavy nodal disease (P 5 .001). The mean breast tumor size was 2.74 6 1.05 cm overall (range, 1.3-5.0 cm), whereas the mean sizes were 2.53 6 1.07 cm (range, 0.8-5.0 cm) for axillary US false-positive tumors and 3.05 6 0.92 cm (range, 0.8-5.0 cm) for axillary US true-positive tumors. Therefore, the falsepositive rate of axillary US in predicting axillae with a heavy nodal tumor burden was higher for T1-stage tumors than for T2-stage tumors (P 5 .001; Table 2 ). Among the tumors of 2 cm or less in diameter, axillary US had a false-positive rate of 77.2% in predicting patients with a heavy nodal burden, whereas it had a false-positive rate of 51.8% among the tumors of greater than 2 cm in diameter. Notably, all 5 patients with primary tumors of 1 cm or smaller were confirmed to have limited nodal disease by pathologic examination in this study.
The data in Table 2 also indicate that patients with ER/PR-negative tumors more frequently had falsepositive US results in predicting axillae with 3 or more axillary nodal metastases (P 5 .000). In this study, 71 cases had ER/PR-negative tumors, 54 of which (76.1%) had a limited nodal tumor burden. However, among the 96 patients with ER-and/or PR-positive tumors, 47 (49.0%) cases had a limited nodal tumor burden in the final pathologic examination.
In this study, the total number of suspicious lymph nodes identified on axillary US imagine for every case was 2.36 6 2.14 (range, 1-10). According to the recommendations of Hieken et al, 9 we stratified our cohort into groups with solitary and multiple suspicious nodes seen on US examinations; 79 cases (47.3%) had solitary suspicious lymph nodes on axillary US imaging, 84.8% (67 of 79) of which had a limited nodal burden in the subsequent definitive histologic examination. The data in Table 3 indicate that axillae with solitary suspicious lymph nodes detected on axillary US imaging more frequently had false-positive results in predicting a heavy nodal burden than those with multiple suspicious nodes detected on axillary US (P 5 .000). Notably, for patients with false-positive results, their most suspicious lymph nodes were more likely to have a thinner cortex (P 5 .000) and a visible fatty hilum (P 5 .046). The mean cortical thickness of the 167 cases overall was 5.0 mm (range, 3.1-14.2 mm), whereas the mean cortical thicknesses were 4.21 6 1.35 mm for cases with false-positive axillary US results and 6.10 6 2.38 mm for those with true-positive results. Moreover, the risk of having false-positive axillary US results was significantly higher in cases with fatty hilum-present nodes than in cases with fatty hilum-absent nodes (63.3% versus 40.0%; P 5 .046). Our previous research found that a cortical thickness of the most suspicious nodes of greater than 3.5 mm was appropriately predictive of patients with 3 or more tumor-involved axillary nodes. 11 Thus, we classified the most suspicious lymph node of each case as follows: grade 1, cortical thickness of 3.5 mm or less but greater than 3.0 mm; and grade 2, cortical thickness of greater than 3.5 mm with or without a lymphatic hilum. Next, compared with patients who had true-positive axillary US results, patients with falsepositive results more frequently had a most suspicious lymph node with a cortical thickness of 3.5 mm or less (P 5 .000; Table 3 ). No correlation was found between (Table 4) . Of these variables, solitary suspicious nodes identified on axillary US imaging were the strongest predictor (odds ratio, 25.4; 95% confidence interval, 4.3-27.2; P 5 .000; Table 4 ). Additionally, a tumor of 2 cm or smaller had an 8.0-fold higher risk, whereas a tumor with an ER/PR-negative status had a 15.9-fold higher risk of a false-positive axillary US result. Axillae that had the most suspicious lymph nodes with a cortical thickness 3.5 mm or less increased the risk of false-positive axillary US results by 6.0-fold compared with those that had the most suspicious lymph nodes with a cortical thickness of greater than 3.5 mm. Similar to the univariate analysis, patient age, tumor histologic type, histologic tumor grade, lymphatic vessel invasion, and expression of c-erbB-2 and Ki 67 did not increase the risk of false-positive axillary US results in predicting axillae with a heavy nodal tumor burden.
Discussion
In the post-ACOSOG Z0011 trial era, preoperative axillary US should be used to identify patients with heavy nodal disease who may still benefit from ALND.
Unfortunately, our data indicated that a positive axillary US result could not differentiate between limited and heavy nodal tumor burdens, which was consistent with previous findings. 8, 9, 12, 13 On the other hand, we found that patients with early-stage breast cancer who had certain primary tumor characteristics and axillary US appearances were at high risk of having a limited axillary tumor burden, for whom limiting US-guided FNAC could avoid overtreatment by ALND for a positive FNAC result.
In our study, the false-positive rate of suspicious axillary US for detecting axillae with 3 or more nodal metastases was 60.3%, which was lower than that in other studies (64.1%-79.8%). 8, 9, 12 This discrepancy might be attributed to 2 factors. First, our patients had a high prevalence of axillary metastases (67.7%) and a greater nodal disease burden (mean number of metastatic lymph nodes, 3.74 6 3.85). Second, we adopted rigorous US criteria for classifying suspicious lymph nodes in this study. Our morphologic criteria were deliberately biased toward specificity to avoid false-positive US findings and unnecessary fine-needle aspiration procedures. This approach might have skewed our rate of false-negative axillary US results for diagnosis of metastatic axillary nodes higher than that of other institutions with more conservative criteria for classifying abnormal lymph nodes. However, the false-negative rate was improved slightly (nearly 4%) when more conservative criteria for classifying suspicious lymph nodes were adopted.
14 Even so, the false-positive rate for detecting any nodal metastasis in our study was 31.1%, which fell within the range established by previous studies (ranging from 7.9%-50.0%). 15 In this study, we found that axillae with the most suspicious lymph nodes that had a cortical thickness 3.5 mm or less but greater than 3.0 mm showed falsepositive axillary US results in predicting a heavy nodal burden more frequently than axillae that had the most suspicious lymph nodes with a cortical thickness of greater than 3.5 mm (88.0% and 48.7%, respectively; P < .001). Our data suggested that a cortical thickness of the most suspicious nodes of greater than 3.5 mm was appropriately predictive of patients with 3 of tumorinvolved axillary nodes, which was in line with the findings of our previous study. 11 Unlike our previous study, however, we not only focused on the imaging features of the most suspicious node but also paid particular attention to the number of suspicious nodes seen on the axillary US examination. Importantly, our experience found that the visualization of multiple suspicious nodes on axillary US imaging was also a predictive factor of patients with 3 or tumor-involved axillary nodes. Our data showed that for patients with solitary suspicious nodes detected by axillary US, 84.8% (67 of 79) of cases had limited positive nodes; however, for patients with multiple suspicious nodes detected by axillary US, 38.6% of cases had limited positive nodes (P 5 .000). Our findings were in agreement with the prior study by Hieken et al. 9 In their study, which enrolled patients with clinically node-negative disease, the rates of 3 or more pathologically metastatic axillary lymph nodes were 13.5% in patients with a solitary suspicious axillary node seen on axillary US imaging and 30.8% in those with multiple abnormal nodes seen on axillary US imaging (P 5 .0008). Together, these data suggest that a thorough axillary US examination in every case with suspicious lymph nodes can help predict the extent of nodal involvement in patients with early-stage invasive breast cancer.
When examining the role of axillary US, it must be considered in combination with the primary breast tumor. This study also found that patients with T1 tumors and ER/PR-negative tumors were more likely to have a false-positive axillary US results for detection of axillae with a heavy nodal tumor burden. Our data showed that the prevalence of the involvement of 3 or more nodes with positive axillary US results was significantly lower in patients with T1-stage tumors than in patients with T2-stage tumors (22.8% and 48.2%, respectively; P 5 .001), which was not surprising given that smaller tumors were more likely to be associated with a lower incidence of axillary nodal disease and a less likelihood of disease affecting 3 or more nodes than larger tumors. 16 As known, the expressions of ER/PR, human epidermal growth factor receptor 2, and Ki-67 proteins are crucial prognostic indicators in patient with breast cancer. Our data showed that the prevalence of the involvement of less than 3 nodes with a positive axillary US result was 76.1% in patients with ER/PR-negative tumors, which was significantly higher than that in patients with ER-and/or PR-positive tumors (49.0%; P 5 .000). Moreover, this association remained significant after the multivariate regression analysis. This counterintuitive result implied that ER/PR-negative tumors had a lower risk of nodal metastases than ER-and/or PR-positive tumors, which appeared to agree with the findings of several previous studies. 17, 18 By contrast, in the univariate analysis data reported by Moorman et al, 12 ER and PR, considered separately, were unrelated to the chance of having more than 2 positive lymph nodes in patients with early-stage breast cancer. The reason for this difference is not clear, and the correlation between these parameters and axillary lymph node metastasis warrants further analysis. Furthermore, previous studies demonstrated that lymphatic vessel invasion was also a powerful predictor of axillary lymph node metastases. It was reported to be associated with a 5.3-to 7.41-fold greater risk of axillary nodal involvement. 17, [19] [20] [21] However, we did not find the presence of lymphatic vessel invasion was an effective predictive factor for patients with breast cancer who had a heavy nodal burden.
Given that knowledge of the axillary nodes status before surgical intervention can assist in surgical planning and may support an informed discussion of management options, the preoperative identification of metastatic disease in patients with abnormal lymph nodes detected by axillary US has a role in streamlining axillary staging. Continued application of preoperatively percutaneous lymph node biopsy is also suggested by our study. It has been well documented that patients with axillary lymph node metastases identified by USguided FNAC have more positive lymph nodes and are more likely to have 3 or more involved nodes than those with sentinel lymph node dissection-identified nodal metastases. 6, 22, 23 However, 39.8% to 49.7% of patients with axillary lymph node metastases identified by USguided FNAC had 1 or 2 positive nodes in the final pathologic examination. 6, 11 Therefore, to cater to the ongoing quest for less-invasive axillary surgery, we advocate that patients fulfilling the ACOSOG Z0011 eligibility criteria with a high risk of having a limited nodal burden should no longer undergo US-guided FNAC and should instead proceed to SLNB. Of course, this strategy for US-guided FNAC may skew our rate of false-negative axillary US results for diagnosis of 3 or more metastatic axillary nodes higher than that of other institutions with more conservative criteria for classifying abnormal lymph nodes. However, for these patients missed by preoperative axillary US, sentinel lymph node surgery to assess the number of positive nodes may be useful. An intraoperative frozen-section examination of the sentinel lymph nodes can evaluate the extent of nodal disease and guide intraoperative decision making regarding whether ALND should be performed.
There were several limitations to this analysis. First, this study was inherently limited by its retrospective design and the use of patient populations from a single institution, possibly restricting its internal and external validity. Second, the performance of axillary US as a diagnostic tool is influenced by the experience of the sonographer and interpreting physician. To record the exact number of suspicious axillary lymph nodes visualized on US imaging, every case was carefully scanned by 2 experienced radiologists to detect as many lymph nodes as possible in this study, a strategy that might have led to the identification of more subtle abnormalities. Several previous studies had reported that most of the patients with slightly abnormal lymph nodes had a limited nodal tumor burden in the final pathologic results. 5, 11, 13 Therefore, the US technique used in this study might be effective in reducing the false-positive rate of axillary US in predicting axillae with a heavy nodal tumor burden. Future studies are needed to assess and compare the sensitivity and accuracy of preoperative US in axillary staging for radiologists with different levels of experience. By combining US features of lymph nodes and the clinical characteristics, the axillary lymph node burden can be predicted. However, lymph nodes visualized on US images cannot be matched individually with lymph nodes under dissection. Therefore, it is very difficult for US to replace SLNB and ALND. Prospective research is warranted.
Taken together, considering the increasing demands for less-invasive axillary surgery, US-guided biopsies of all patients with any abnormal lymph nodes detected by axillary US should not be adopted. Our data indicated that axillary US had a false-positive rate of 60.5% in patients with breast cancer who had a heavy nodal burden, and additionally, certain primary tumor characteristics and US appearances of axillae were significantly correlated with the false-positive results. Specifically, patients with a T1-stage tumor, an ER/PR-negative tumor, solitary suspicious nodes identified by axillary US, and a cortical thickness of the most suspicious lymph node of 3.5 mm or less are more likely to have limited nodal disease in the final pathologic results. Therefore, for patients with early-stage breast cancer in the post-ACOSOG Z0011 trial era, it is particularly important to conduct a secondary evaluation either clinically or by axillary imaging before the use of US-guided biopsy of suspicious nodes.
